Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,055,287 papers from all fields of science
Search
Sign In
Create Free Account
patritumab
A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
AMG 888
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
High prevalence of activated protein C resistance associated with high avidity anti-protein C antibodies in various antiphospholipid syndrome clinical phenotypes
M. Efthymiou
,
I. Mackie
,
P. Lane
,
D. Erkan
,
H. Cohen
2017
Corpus ID: 196523521
Background: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent and/or metastatic (R/M…
Expand
2016
2016
Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.
K. Harrington
,
M. Forster
,
+7 authors
J. Greenberg
2016
Corpus ID: 59242697
TPS6104Background: P is a fully human monoclonal antibody against human epidermal growth factor receptor 3. P blocks activation…
Expand
2016
2016
Patritumab or Placebo Plus Cetuximab and Platinum-Based Therapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN): a Phase 2 Study
K. Harrington
,
M. Forster
,
+7 authors
J. Greenberg
2016
Corpus ID: 80527196
BACKGROUND: P is a fully human monoclonal antibody against human epidermal growth factor receptor 3. P blocks activation by the…
Expand
2014
2014
Phase 3 study of patritumab plus erlotinib in EGFR wild-type subjects with advanced non-small cell lung cancer
L. Paz-Ares
,
J. Pawel
,
+4 authors
R. Beckman
2014
Corpus ID: 97005724
• Many patients with advanced non–small cell lung cancer (NSCLC) initially benefit from treatment with anti–epidermal growth…
Expand
2014
2014
Patritumab: Anti-HER3 monoclonal antibody, oncolytic
K. Haddley
Drugs of the future
2014
Corpus ID: 57499007
2013
2013
Abstract P4-16-09: Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+ metastatic breast cancer (MBC)
S. Carraro
,
D. Campos
,
+6 authors
E. Cazap
2013
Corpus ID: 71481668
Background: Patritumab is a fully human anti-HER3 monoclonal antibody that has shown potent antitumor activity in vivo . HER3 is…
Expand
2013
2013
Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC).
N. Yamamoto
,
A. Horiike
,
+5 authors
T. Tamura
2013
Corpus ID: 87387324
Background: HER3 is a key dimerization partner for HER-family members that activates oncogenic signaling pathways. Patritumab is…
Expand